<DOC>
	<DOC>NCT00204633</DOC>
	<brief_summary>The aim is to determine the frequency of RBC transfusion in patients with metastatic "poor prognosis" germ cell tumor during high-dose chemotherapy (HD-VIP, level 6) with or without Darbepoetin alfa</brief_summary>
	<brief_title>Darbepoetin Alfa in Patients With "Poor Prognosis" Germ Cell Tumor Treated With High-Dose Chemotherapy (HD-VIP)</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
	<mesh_term>Dysgerminoma</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Poor prognosis" according IGCCCGcriteria: Primary mediastinal tumor Gonadal/retroperitoneal germ cell tumor with visceral metastases except of lung Poor marker: AFP &gt; 10.000 ng/ml or betaHCG &gt; 10.000 ng/ml (50.000 IU/l) andd LDH &gt;10 x upper normal limit No previous chemotherapy Age &gt; 18 years PerformanceStatus: WHO =&lt; 2 Written informed consent Ability to give informed consent Hemolysis Hematological disease with insufficient erythropoiesis Patients without sufficient treatment of sideropenia, folate deficiency or vitamin B12 deficiency Uncontrolled arterial hypertension Treatment with rhErythropoetin during trial Creatinin clearance &lt; 50 ml/min Insufficient bone marrow function (WBC count &lt; 3.000/ml or platelets &lt; 100.000/Âµl) Other major symptomatic or uncontrolled illnesses not allowing to complete treatment protocol with the exception of symptoms caused by the primary disease Second malignancy, except of completely resected basal cell carcinoma of the skin</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>